Sentence: Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma : a multicentre phase II study .
Drug combination annotation:
[{'class': 'POS', 'spans': ['bortezomib', 'rituximab'], 'is_context_needed': True}]